La. Admin. Code tit. 46 § XXXIII-134

Current through Register Vol. 50, No. 12, December 20, 2024

Section XXXIII-134 - Prescription Monitoring Program

A. Pursuant to R.S. 40:973(A), all dentists who have obtained a controlled dangerous substance license issued by the Board of Pharmacy shall automatically be enrolled in the Prescription Monitoring Program established in R.S. 40:1001 et seq.

B. A prescriber or his delegate shall access and review the patients record in the Prescription Monitoring Program and review the patients record at least every 90 days if the patients course of treatment continues for more than 90 days. The requirement established in this Section shall not apply in the following instances.

1. The drug is prescribed or administered to a hospice patient or to any other patient who has been diagnosed as terminally ill.

2. The drug is prescribed or administered for the treatment of cancer-related chronic or intractable pain.

3. The drug is ordered or administered to a patient being treated in a hospital.

4. The Prescription Monitoring Program is inaccessible or not functioning properly due to an internal or external electronic issue. However, the prescriber or his delegate shall check the Prescription Monitoring Program once the electronic accessibility has been restored and note the cause for the delay in the patients chart.

5. No more than a single seven-day supply of the drug is prescribed or administered to a patient.

C. Failure to comply with this Rule shall constitute a violation of R.S. 37:776(A)(6) and/or 37:776(A)(24) and may subject the dentist to punishment, penalty, sanction or remediation as provided for in the Dental Practice Act.

La. Admin. Code tit. 46, § XXXIII-134

Promulgated by the Department of Health, Board of Dentistry, LR 4445 (1/1/2018).

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:760(8).